A molecular guide to systemic therapy in salivary gland carcinoma
Salivary gland carcinomas (SGC) are a rare and variable group of head and neck cancers with historically poor response to cytotoxic chemotherapy and immunotherapy in the recurrent, advanced, and metastatic settings. In the last decade, a number of targetable molecular alterations have been identifie...
Saved in:
| Published in: | Head & neck Vol. 45; no. 5; pp. 1315 - 1326 |
|---|---|
| Main Authors: | , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Hoboken, USA
John Wiley & Sons, Inc
01-05-2023
Wiley Subscription Services, Inc |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Salivary gland carcinomas (SGC) are a rare and variable group of head and neck cancers with historically poor response to cytotoxic chemotherapy and immunotherapy in the recurrent, advanced, and metastatic settings. In the last decade, a number of targetable molecular alterations have been identified in SGCs including HER2 upregulation, androgen receptor overexpression, Notch receptor activation, NTRK gene fusions, and RET alterations which have dramatically improved treatment outcomes in this disease. Here, we review the landscape of precision therapy in SGC including current options for systemic management, ongoing clinical trials, and promising future directions. |
|---|---|
| AbstractList | Salivary gland carcinomas (SGC) are a rare and variable group of head and neck cancers with historically poor response to cytotoxic chemotherapy and immunotherapy in the recurrent, advanced, and metastatic settings. In the last decade, a number of targetable molecular alterations have been identified in SGCs including HER2 upregulation, androgen receptor overexpression, Notch receptor activation, NTRK gene fusions, and RET alterations which have dramatically improved treatment outcomes in this disease. Here, we review the landscape of precision therapy in SGC including current options for systemic management, ongoing clinical trials, and promising future directions. |
| Author | Ulanja, Mark B. Bowles, Daniel W. Weaver, Alice N. Mandair, Divneet Lakritz, Stephanie |
| Author_xml | – sequence: 1 givenname: Alice N. orcidid: 0000-0002-9398-1471 surname: Weaver fullname: Weaver, Alice N. organization: University of Colorado School of Medicine – sequence: 2 givenname: Stephanie surname: Lakritz fullname: Lakritz, Stephanie organization: University of Colorado School of Medicine – sequence: 3 givenname: Divneet surname: Mandair fullname: Mandair, Divneet organization: University of San Francisco California – sequence: 4 givenname: Mark B. surname: Ulanja fullname: Ulanja, Mark B. organization: Christus Ochsner St. Patrick Hospital – sequence: 5 givenname: Daniel W. orcidid: 0000-0003-1406-0963 surname: Bowles fullname: Bowles, Daniel W. email: daniel.bowles@cuanschutz.edu organization: Rocky Mountain Regional Veterans Affairs Medical Center |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36859797$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kD1PwzAQhi1URD9g4A8gSywwpHVsJ07GqhSKVIkFZsuxndZVEhe7AeXf45J2QWLxWXePHt29YzBobKMBuI3RNEYIz7ZaTTEjiF2AUYxyFiFC2eD4pyQKbToEY-93CCGSUnwFhiTNkpzlbATmc1jbSsu2Eg5uWqM0PFjoO3_QtZHwsNVO7DtoGuhFZb6E6-CmEo2CUjhpGluLa3BZisrrm1OdgI_n5ftiFa3fXl4X83UkSUJYVKZayhQxFSutZJ7kWUZELDJUFEmupMoLjAljJRHFcUoFLahOUlmSMqWixGQCHnrv3tnPVvsDr42XugrbaNt6jlkWp5iG0wJ6_wfd2dY1YbtABXl4chaox56SznrvdMn3ztThQh4jfsyVh1z5b66BvTsZ26IO3TN5DjIAsx74NpXu_jfx1fKpV_4AW6qCuw |
| CitedBy_id | crossref_primary_10_1055_a_2150_2670 crossref_primary_10_1002_hed_27565 crossref_primary_10_1002_hed_27664 crossref_primary_10_1002_hed_27376 crossref_primary_10_1053_j_semdp_2024_04_002 crossref_primary_10_3390_biomedicines12050957 |
| Cites_doi | 10.1002/hed.25035 10.1615/CritRevOncog.2018027598 10.1002/cncr.32754 10.1102/1470‐7330.2007.0008 10.1200/JCO.2022.40.16_suppl.3094 10.1002/hed.23940 10.1002/lary.26516 10.1001/jamaoto.2015.3270 10.1016/s1470‐2045(19)30691‐6 10.1007/s12105‐021‐01376‐8 10.1200/jco.2007.11.8612 10.3332/ecancer.2020.1055 10.1002/hed.25891 10.1038/bjc.2013.468 10.1001/archoto.2009.70 10.1016/j.oraloncology.2008.07.010 10.1155/2019/5103496 10.1016/j.oraloncology.2016.06.019 10.1007/s10006‐012‐0350‐9 10.21873/anticanres.11659 10.1186/1752‐1947‐2‐320 10.1002/hed.23925 10.1016/s2213‐8587(21)00120‐0 10.1177/17588359211013626 10.1016/j.oraloncology.2021.105366 10.1158/0008‐5472.Can‐10‐1758 10.3389/fonc.2020.580141 10.1007/s12105‐022‐01420‐1 10.1200/jco.2005.05.3025 10.1056/NEJMoa1714448 10.1172/jci.insight.139497 10.1016/s1470‐2045(10)70245‐x 10.1093/oxfordjournals.annonc.a010770 10.7150/thno.38501 10.1002/ijc.31353 10.1093/annonc/mdw287 10.1186/s13550‐021‐00866‐8 10.1159/000488669 10.21037/cco.2020.03.07 10.14694/EdBook_AM.2013.33.257 10.1016/j.oraloncology.2017.09.008 10.1001/archotol.1981.00790480015004 10.1200/jco.18.00545 10.1001/archoto.2011.158 10.1158/1078‐0432.Ccr‐13‐2098 10.1200/JCO.21.00449 10.1186/s13014‐018‐1130‐y 10.1200/jop.2017.026856 10.3389/fonc.2021.693394 10.1007/s00405‐021‐07024‐9 10.1001/jamaoto.2015.3930 10.1016/j.oooo.2020.04.007 10.1016/j.adro.2017.03.008 10.1093/jnci/djx017 10.1097/coc.0000000000000157 10.1016/j.annonc.2019.11.018 10.1111/apm.12901 10.1634/theoncologist.2012‐0369 10.1002/hed.23647 10.1016/j.ijscr.2015.09.031 10.1016/j.nucmedbio.2021.04.003 10.3342/ceo.2011.4.4.188 10.4103/jcis.JCIS_46_18 10.1186/s12885‐015‐1827‐3 10.1200/jco.18.01859 10.1200/jco.21.00468 10.1056/NEJMoa2005651 10.1016/j.critrevonc.2014.02.002 10.1097/PAS.0b013e3181d9efcc 10.18632/oncotarget.13952 10.1200/JCO.2021.39.15_suppl.3079 10.1016/s1470‐2045(21)00247‐3 10.1200/JCO.2019.37.15_suppl.6001 10.1200/JCO.2022.40.16_suppl.6020 10.1097/cco.0000000000000527 10.1016/j.joms.2009.09.064 10.1016/j.ijrobp.2004.03.018 10.1002/1097‐0142(19911101)68:9<1874::aid‐cncr2820680904>3.0.co;2‐s 10.1016/j.ejca.2018.12.035 10.1200/JCO.2022.40.16_suppl.6046 10.1002/lary.24254 10.1002/cncr.21083 10.1016/j.oraloncology.2015.10.002 10.1186/s12885‐018‐4578‐0 10.1016/j.ejca.2011.06.012 10.1172/jci128227 10.1097/coc.0000000000000429 10.1002/1097‐0142(20010201)91:3<541::aid‐cncr1032>3.0.co;2‐y 10.1038/s41392‐022‐00934‐y 10.1038/s41467‐018‐08069‐x 10.1056/NEJMoa2005653 10.1016/j.ctrv.2020.102069 10.1002/gcc.20306 10.1200/JCO.2019.37.15_suppl.6083 10.1093/annonc/mdx771 10.1158/2159‐8290.Cd‐19‐1014 10.1200/jco.22.00229 10.1002/hed.24933 10.1016/j.critrevonc.2020.102959 10.1002/lio2.326 10.1093/oxfordjournals.annonc.a058665 10.1097/pas.0000000000001065 10.1002/hed.23350 10.4103/jcis.JCIS_45_18 10.1097/coc.0000000000000386 10.1097/md.0000000000005964 10.1097/pas.0000000000000972 10.4103/joc.Joc_165_18 10.1016/s1470‐2045(19)30856‐3 10.1084/jem.20180939 10.1007/s00405‐015‐3855‐7 10.1001/archotol.130.7.849 10.1093/jjco/hyn045 10.1016/j.oraloncology.2015.02.096 10.1007/bf02574486 |
| ContentType | Journal Article |
| Copyright | 2023 Wiley Periodicals LLC. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA. 2023 Wiley Periodicals LLC. |
| Copyright_xml | – notice: 2023 Wiley Periodicals LLC. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA. – notice: 2023 Wiley Periodicals LLC. |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QP 7TK K9. 7X8 |
| DOI | 10.1002/hed.27307 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Calcium & Calcified Tissue Abstracts Neurosciences Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Health & Medical Complete (Alumni) Calcium & Calcified Tissue Abstracts Neurosciences Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE ProQuest Health & Medical Complete (Alumni) CrossRef |
| Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 1097-0347 |
| EndPage | 1326 |
| ExternalDocumentID | 10_1002_hed_27307 36859797 HED27307 |
| Genre | reviewArticle Journal Article Review |
| GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 36B 3O- 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABEML ABIJN ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADZMN ADZOD AEEZP AEIGN AEIMD AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DUUFO EBD EBS EJD EMB EMOBN F00 F01 F04 F5P FEDTE G-S G.N GNP GODZA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M6P MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO ROL RWI RX1 RYL SAMSI SUPJJ SV3 TEORI UB1 V2E W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WJL WOHZO WQJ WRC WUP WVDHM WWO WXI WXSBR X7M XG1 XPP XV2 ZGI ZXP ZZTAW ~IA ~WT CGR CUY CVF ECM EIF NPM AAMNL AAYXX CITATION 7QP 7TK K9. 7X8 |
| ID | FETCH-LOGICAL-c3537-f6ecc607d1dedc959883a1a80bb59dcd9b22377f3abc9594a4b4e56cf3f64af23 |
| IEDL.DBID | 33P |
| ISSN | 1043-3074 |
| IngestDate | Fri Aug 16 00:28:50 EDT 2024 Thu Oct 10 18:41:28 EDT 2024 Fri Nov 22 01:14:46 EST 2024 Sat Sep 28 08:17:37 EDT 2024 Sat Aug 24 01:00:12 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | salivary gland cancer adenoid cystic carcinoma mucoepidermoid carcinoma salivary duct carcinoma precision therapy |
| Language | English |
| License | 2023 Wiley Periodicals LLC. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3537-f6ecc607d1dedc959883a1a80bb59dcd9b22377f3abc9594a4b4e56cf3f64af23 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| ORCID | 0000-0002-9398-1471 0000-0003-1406-0963 |
| PMID | 36859797 |
| PQID | 2795927997 |
| PQPubID | 996355 |
| PageCount | 12 |
| ParticipantIDs | proquest_miscellaneous_2781624368 proquest_journals_2795927997 crossref_primary_10_1002_hed_27307 pubmed_primary_36859797 wiley_primary_10_1002_hed_27307_HED27307 |
| PublicationCentury | 2000 |
| PublicationDate | May 2023 2023-05-00 20230501 |
| PublicationDateYYYYMMDD | 2023-05-01 |
| PublicationDate_xml | – month: 05 year: 2023 text: May 2023 |
| PublicationDecade | 2020 |
| PublicationPlace | Hoboken, USA |
| PublicationPlace_xml | – name: Hoboken, USA – name: United States – name: Houston |
| PublicationTitle | Head & neck |
| PublicationTitleAlternate | Head Neck |
| PublicationYear | 2023 |
| Publisher | John Wiley & Sons, Inc Wiley Subscription Services, Inc |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: Wiley Subscription Services, Inc |
| References | 2017; 40 2001; 91 2009; 45 2015; 37 2017; 8 2019; 2019 2017; 2 2021; 22 2019; 10 2008; 38 2020; 126 2019; 127 2020; 14 2018; 41 2018; 40 2011; 12 2012; 16 2020; 10 2005; 61 1981; 107 2019; 129 2008; 2 2016; 38 2018; 42 2017; 9 2016; 36 2016; 142 1993; 4 2014; 20 2013; 18 2018; 8 2017; 74 2010; 68 2017; 37 2021; 98‐99 2006; 24 2018; 215 2022; 40 2005; 103 2004; 130 2021; 39 2021; 119 2018; 378 2020; 9 2007; 7 2020; 89 2010; 70 2017; 127 2007; 25 2016; 273 1996; 7 2019; 110 2014; 124 2010; 34 2021; 9 2011; 137 2018; 29 2015; 15 2021; 6 2018; 143 2019; 4 2014; 91 2015; 16 2002; 9 2013; 109 2019; 31 2020; 383 2015; 51 2019; 37 2019; 36 2009; 135 2018; 23 2011; 4 2022; 279 2021; 13 2017; 109 2018; 18 2017; 96 2021; 11 2020; 31 2006; 45 2020; 152 2019; 41 1991; 68 2022; 7 2014; 36 2016; 60 2013 2020; 21 2021; 132 2011; 47 2018; 11 2016; 27 2022; 16 2018; 14 2018; 13 e_1_2_9_75_1 e_1_2_9_98_1 e_1_2_9_52_1 e_1_2_9_79_1 e_1_2_9_94_1 e_1_2_9_10_1 e_1_2_9_56_1 e_1_2_9_33_1 e_1_2_9_90_1 e_1_2_9_71_1 e_1_2_9_103_1 e_1_2_9_107_1 e_1_2_9_14_1 e_1_2_9_37_1 e_1_2_9_18_1 e_1_2_9_41_1 e_1_2_9_64_1 e_1_2_9_87_1 e_1_2_9_22_1 e_1_2_9_45_1 e_1_2_9_68_1 e_1_2_9_83_1 e_1_2_9_6_1 e_1_2_9_60_1 e_1_2_9_2_1 e_1_2_9_111_1 e_1_2_9_115_1 e_1_2_9_26_1 e_1_2_9_49_1 e_1_2_9_30_1 e_1_2_9_53_1 e_1_2_9_99_1 e_1_2_9_72_1 e_1_2_9_11_1 e_1_2_9_57_1 e_1_2_9_95_1 e_1_2_9_76_1 e_1_2_9_91_1 e_1_2_9_102_1 e_1_2_9_106_1 e_1_2_9_15_1 e_1_2_9_38_1 e_1_2_9_19_1 e_1_2_9_42_1 e_1_2_9_88_1 e_1_2_9_61_1 e_1_2_9_46_1 e_1_2_9_84_1 e_1_2_9_23_1 e_1_2_9_65_1 e_1_2_9_80_1 e_1_2_9_5_1 e_1_2_9_114_1 e_1_2_9_118_1 e_1_2_9_9_1 e_1_2_9_27_1 e_1_2_9_69_1 e_1_2_9_110_1 e_1_2_9_31_1 e_1_2_9_50_1 e_1_2_9_73_1 e_1_2_9_35_1 e_1_2_9_77_1 e_1_2_9_96_1 e_1_2_9_12_1 e_1_2_9_54_1 e_1_2_9_92_1 e_1_2_9_109_1 e_1_2_9_101_1 e_1_2_9_105_1 e_1_2_9_39_1 e_1_2_9_16_1 e_1_2_9_58_1 e_1_2_9_20_1 e_1_2_9_62_1 e_1_2_9_89_1 e_1_2_9_24_1 e_1_2_9_43_1 e_1_2_9_66_1 e_1_2_9_85_1 e_1_2_9_8_1 e_1_2_9_81_1 e_1_2_9_113_1 e_1_2_9_117_1 e_1_2_9_28_1 e_1_2_9_47_1 e_1_2_9_74_1 e_1_2_9_51_1 e_1_2_9_78_1 e_1_2_9_13_1 e_1_2_9_32_1 e_1_2_9_55_1 e_1_2_9_97_1 e_1_2_9_93_1 e_1_2_9_108_1 e_1_2_9_70_1 e_1_2_9_100_1 e_1_2_9_104_1 Sayan M (e_1_2_9_34_1) 2016; 36 e_1_2_9_17_1 e_1_2_9_36_1 e_1_2_9_59_1 e_1_2_9_63_1 e_1_2_9_40_1 e_1_2_9_21_1 e_1_2_9_67_1 e_1_2_9_44_1 e_1_2_9_86_1 e_1_2_9_7_1 e_1_2_9_82_1 e_1_2_9_3_1 e_1_2_9_112_1 e_1_2_9_116_1 e_1_2_9_25_1 e_1_2_9_48_1 WHO (e_1_2_9_4_1) 2017 e_1_2_9_29_1 |
| References_xml | – volume: 38 start-page: 414 issue: 6 year: 2008 end-page: 418 article-title: Mucoepidermoid carcinoma of the head and neck: clinical analysis of 43 patients publication-title: Jpn J Clin Oncol – start-page: 257 year: 2013 end-page: 263 article-title: Salivary gland cancer: an update on present and emerging therapies publication-title: Am Soc Clin Oncol Educ Book – volume: 2 start-page: 320 year: 2008 article-title: Cetuximab in the treatment of metastatic mucoepidermoid carcinoma of the salivary glands: a case report and review of literature publication-title: J Med Case Reports – volume: 13 start-page: 184 issue: 1 year: 2018 article-title: Nodal failure patterns and utility of elective nodal irradiation in submandibular gland carcinoma treated with postoperative radiotherapy: a multicenter experience publication-title: Radiat Oncol – volume: 91 start-page: 541 issue: 3 year: 2001 end-page: 547 article-title: Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies publication-title: Cancer – volume: 91 start-page: 142 issue: 2 year: 2014 end-page: 158 article-title: A rationale for chemoradiation (vs radiotherapy) in salivary gland cancers? On behalf of the REFCOR (French rare head and neck cancer network) publication-title: Crit Rev Oncol Hematol – volume: 8 start-page: 48 year: 2018 article-title: Review of the major and minor salivary glands, part 2: neoplasms and tumor‐like lesions publication-title: J Clin Imaging Sci. – volume: 273 start-page: 3511 issue: 11 year: 2016 end-page: 3531 article-title: Salivary acinic cell carcinoma: reappraisal and update publication-title: Eur Arch Otorhinolaryngol – volume: 152 year: 2020 article-title: Major and minor salivary gland tumours publication-title: Crit Rev Oncol Hematol – volume: 96 issue: 5 year: 2017 article-title: Risk factors and prognosis for salivary gland adenoid cystic carcinoma in southern China: a 25‐year retrospective study publication-title: Medicine (Baltimore) – volume: 23 start-page: 139 issue: 3–4 year: 2018 end-page: 151 article-title: Current state of knowledge on salivary gland cancers publication-title: Crit Rev Oncog – volume: 16 start-page: 427 issue: 2 year: 2022 end-page: 433 article-title: Immunohistochemical reactivity of prostate‐specific membrane antigen in salivary Gland tumors publication-title: Head Neck Pathol – volume: 41 start-page: 3670 issue: 10 year: 2019 end-page: 3676 article-title: Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract publication-title: Head Neck – volume: 29 start-page: 979 issue: 4 year: 2018 end-page: 984 article-title: A prospective phase II study of combined androgen blockade in patients with androgen receptor‐positive metastatic or locally advanced unresectable salivary gland carcinoma publication-title: Ann Oncol – volume: 383 start-page: 825 issue: 9 year: 2020 end-page: 835 article-title: Efficacy of Selpercatinib in RET‐altered thyroid cancers publication-title: New Engl J Med – volume: 4 start-page: 188 issue: 4 year: 2011 end-page: 192 article-title: Clinical analysis of acinic cell carcinoma in parotid gland publication-title: Clin Exp Otorhinolaryngol – volume: 127 start-page: 240 issue: 5 year: 2019 end-page: 264 article-title: An update on head and neck cancer: new entities and their histopathology, molecular background, treatment, and outcome publication-title: APMIS – volume: 39 start-page: 4061 issue: 36 year: 2021 end-page: 4068 article-title: Abiraterone acetate in patients with castration‐resistant, androgen receptor–expressing salivary Gland cancer: a phase II trial publication-title: J Clin Oncol – volume: 37 start-page: 125 issue: 2 year: 2019 end-page: 134 article-title: Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2‐positive salivary duct carcinoma publication-title: J Clin Oncol – volume: 98‐99 start-page: 30 year: 2021 end-page: 39 article-title: The salivary glands as a dose limiting organ of PSMA‐ targeted radionuclide therapy: a review of the lessons learnt so far publication-title: Nucl Med Biol – volume: 126 start-page: 1888 issue: 9 year: 2020 end-page: 1894 article-title: Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: activity and quality of life publication-title: Cancer – volume: 37 start-page: 6001 issue: 15_suppl year: 2019 article-title: Ado‐trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): results from a phase II basket trial publication-title: J Clin Oncol – volume: 142 start-page: 489 issue: 5 year: 2016 end-page: 495 article-title: A 20‐year review of 75 cases of salivary duct carcinoma publication-title: JAMA Otolaryngol Head Neck Surg – volume: 51 start-page: 438 issue: 5 year: 2015 end-page: 445 article-title: Survival benefit for adjuvant radiation therapy in minor salivary gland cancers publication-title: Oral Oncol – volume: 21 start-page: 531 issue: 4 year: 2020 end-page: 540 article-title: Larotrectinib in patients with TRK fusion‐positive solid tumours: a pooled analysis of three phase 1/2 clinical trials publication-title: Lancet Oncol – volume: 20 start-page: 246 issue: 1 year: 2014 end-page: 252 article-title: Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials publication-title: Clin Cancer Res – volume: 215 start-page: 2673 issue: 10 year: 2018 end-page: 2685 article-title: Zebrafish blastomere screen identifies retinoic acid suppression of MYB in adenoid cystic carcinoma publication-title: J Exp Med – volume: 378 start-page: 731 issue: 8 year: 2018 end-page: 739 article-title: Efficacy of larotrectinib in TRK fusion‐positive cancers in adults and children publication-title: New Engl J Med – volume: 22 start-page: 959 issue: 7 year: 2021 end-page: 969 article-title: Pralsetinib for RET fusion‐positive non‐small‐cell lung cancer (ARROW): a multi‐cohort, open‐label, phase 1/2 study publication-title: Lancet Oncol – volume: 21 start-page: 271 issue: 2 year: 2020 end-page: 282 article-title: Entrectinib in patients with advanced or metastatic NTRK fusion‐positive solid tumours: integrated analysis of three phase 1‐2 trials publication-title: Lancet Oncol – volume: 38 start-page: 620 issue: 4 year: 2016 end-page: 627 article-title: Adenoid cystic carcinoma: a review of recent advances, molecular targets, and clinical trials publication-title: Head Neck – volume: 2 start-page: 159 issue: 2 year: 2017 end-page: 166 article-title: Adjuvant radiation for salivary gland malignancies is associated with improved survival: a National Cancer Database analysis publication-title: Adv Radiat Oncol – volume: 39 start-page: 3079 issue: 15_suppl year: 2021 article-title: Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion‐positive solid tumors: update from the ARROW trial publication-title: J Clin Oncol – volume: 40 start-page: 3094 issue: 16_suppl year: 2022 article-title: Tumor agnostic efficacy of selpercatinib in patients with RET fusion+ solid tumors: a global, multicenter, registrational trial update (LIBRETTO‐001) publication-title: J Clin Oncol – volume: 4 start-page: 632 issue: 6 year: 2019 end-page: 639 article-title: Outcomes and prognostic factors in parotid gland malignancies: a 10‐year single center experience publication-title: Laryngoscope Investig Otolaryngol – volume: 42 start-page: 1121 issue: 8 year: 2018 end-page: 1126 article-title: Salivary secretory carcinoma with a novel ETV6‐MET fusion: expanding the molecular Spectrum of a recently described entity publication-title: Am J Surg Pathol – volume: 18 start-page: 672 issue: 1 year: 2018 article-title: Treatment outcomes in metastatic and localized high‐grade salivary gland cancer: high chance of cure with surgery and post‐operative radiation in T1‐2 N0 high‐grade salivary gland cancer publication-title: BMC Cancer – volume: 103 start-page: 2544 issue: 12 year: 2005 end-page: 2550 article-title: Radiotherapy alone or combined with surgery for salivary gland carcinoma publication-title: Cancer – volume: 10 start-page: 368 issue: 1 year: 2019 article-title: Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands publication-title: Nat Commun – volume: 60 start-page: 146 year: 2016 end-page: 156 article-title: Photon beam and particle radiotherapy: present and future publication-title: Oral Oncol – volume: 13 year: 2021 article-title: Apatinib in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a single‐arm, phase II prospective study publication-title: Ther Adv Med Oncol – volume: 10 year: 2020 article-title: Salivary gland carcinoma: novel targets to overcome treatment resistance in advanced disease publication-title: Front Oncol – volume: 31 start-page: 412 issue: 3 year: 2020 end-page: 421 article-title: Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study publication-title: Ann Oncol – volume: 40 start-page: 6020 issue: 16_suppl year: 2022 article-title: A phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, rivoceranib, for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC) publication-title: J Clin Oncol – volume: 142 start-page: 234 issue: 3 year: 2016 end-page: 240 article-title: Role of CRTC1/MAML2 translocation in the prognosis and clinical outcomes of Mucoepidermoid carcinoma publication-title: JAMA Otolaryngol Head Neck Surg – volume: 18 start-page: 294 issue: 3 year: 2013 end-page: 300 article-title: Trastuzumab for the treatment of salivary duct carcinoma publication-title: Oncologist – volume: 7 start-page: 52 issue: 1 year: 2007 end-page: 62 article-title: Imaging of salivary gland tumours publication-title: Cancer Imaging – volume: 40 start-page: 55 issue: 1 year: 2018 end-page: 62 article-title: Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck publication-title: Head Neck – volume: 40 start-page: 605 issue: 3 year: 2018 end-page: 613 article-title: Androgen deprivation therapy for androgen receptor‐positive advanced salivary duct carcinoma: a nationwide case series of 35 patients in The Netherlands publication-title: Head Neck – volume: 127 start-page: 2057 issue: 9 year: 2017 end-page: 2062 article-title: Patterns of care and survival of adjuvant radiation for major salivary adenoid cystic carcinoma publication-title: Laryngoscope – volume: 37 start-page: 3045 issue: 6 year: 2017 end-page: 3052 article-title: Clinical outcomes and prognostic factors of adenoid cystic carcinoma of the head and neck publication-title: Anticancer Res – volume: 47 start-page: 2512 issue: 17 year: 2011 end-page: 2516 article-title: Tumour growth rates and RECIST criteria in early drug development publication-title: Eur J Cancer – volume: 7 start-page: 95 issue: 1 year: 2022 article-title: Notch signaling pathway: architecture, disease, and therapeutics publication-title: Signal Transduct Target Ther – volume: 383 start-page: 813 issue: 9 year: 2020 end-page: 824 article-title: Efficacy of Selpercatinib in RET fusion–positive non–small‐cell lung cancer publication-title: New Engl J Med. – volume: 132 start-page: e143 issue: 4 year: 2021 end-page: e152 article-title: A systematic review of secretory carcinoma of the salivary gland: where are we? publication-title: Oral Surg Oral Med Oral Pathol Oral Radiol – volume: 68 start-page: 1874 issue: 9 year: 1991 end-page: 1877 article-title: Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients publication-title: Cancer – volume: 36 start-page: 694 issue: 5 year: 2014 end-page: 701 article-title: Survival rates and prognostic factors for infiltrating salivary duct carcinoma: analysis of 228 cases from the surveillance, epidemiology, and end results database publication-title: Head Neck – volume: 16 start-page: 40 issue: 1 year: 2022 end-page: 53 article-title: Update from the 5th edition of the World Health Organization classification of head and neck tumors: salivary glands publication-title: Head Neck Pathol – volume: 9 start-page: 491 issue: 8 year: 2021 end-page: 501 article-title: Pralsetinib for patients with advanced or metastatic RET‐altered thyroid cancer (ARROW): a multi‐cohort, open‐label, registrational, phase 1/2 study publication-title: Lancet Diabetes Endocrinol – volume: 74 start-page: 40 year: 2017 end-page: 48 article-title: Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy publication-title: Oral Oncol – volume: 24 start-page: 2673 issue: 17 year: 2006 end-page: 2678 article-title: Systemic therapy in the palliative management of advanced salivary gland cancers publication-title: J Clin Oncol – volume: 14 start-page: 99 issue: 2 year: 2018 end-page: 108 article-title: Cancers of the major salivary gland publication-title: J Oncol Pract – volume: 38 start-page: 724 issue: 5 year: 2016 end-page: 731 article-title: Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor–positive salivary gland cancers publication-title: Head Neck – volume: 37 start-page: 1529 issue: 18 year: 2019 end-page: 1537 article-title: Phase II study of Lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma publication-title: J Clin Oncol – volume: 25 start-page: 3978 issue: 25 year: 2007 end-page: 3984 article-title: Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands publication-title: J Clin Oncol – volume: 130 start-page: 849 issue: 7 year: 2004 end-page: 856 article-title: Mucoepidermoid carcinoma of the parotid gland: the Mayo clinic experience publication-title: Arch Otolaryngol Head Neck Surg – volume: 40 start-page: 6046 issue: suppl 16 year: 2022 article-title: Results of ACCURACY: a phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic adenoid cystic carcinoma harboring notch activating mutations publication-title: J Clin Oncol – volume: 89 year: 2020 article-title: Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: a systematic review publication-title: Cancer Treat Rev – volume: 45 start-page: 470 issue: 5 year: 2006 end-page: 481 article-title: Molecular classification of mucoepidermoid carcinomas‐prognostic significance of the MECT1‐MAML2 fusion oncogene publication-title: Genes Chromosomes Cancer – volume: 31 start-page: 169 issue: 3 year: 2019 end-page: 174 article-title: New approaches in salivary gland carcinoma publication-title: Curr Opin Oncol – volume: 70 start-page: 9143 issue: 22 year: 2010 end-page: 9152 article-title: Mammalian target of rapamycin‐dependent acinar cell neoplasia after inactivation of Apc and Pten in the mouse salivary gland: implications for human acinic cell carcinoma publication-title: Cancer Res – volume: 2019 year: 2019 article-title: Secretory carcinoma of the parotid: making the correct diagnosis of a rare salivary Gland carcinoma when molecular biology testing is not available publication-title: Case Rep Pathol – volume: 6 start-page: 1 issue: 7 year: 2021 end-page: 18 article-title: The CRTC1‐MAML2 fusion is the major oncogenic driver in mucoepidermoid carcinoma publication-title: JCI Insight – volume: 61 start-page: 103 issue: 1 year: 2005 end-page: 111 article-title: The role of radiotherapy in the treatment of malignant salivary gland tumors publication-title: Int J Radiat Oncol Biol Phys – volume: 37 start-page: 644 issue: 5 year: 2015 end-page: 649 article-title: Phase II study of gefitinib in patients with advanced salivary gland cancers publication-title: Head Neck – volume: 107 start-page: 739 issue: 12 year: 1981 end-page: 741 article-title: Cisplatin therapy for adenoid cystic carcinoma publication-title: Arch Otolaryngol – volume: 9 start-page: 688 issue: 7 year: 2002 end-page: 695 article-title: Mucoepidermoid carcinoma of the salivary glands: clinicopathologic review of 108 patients treated at the National Cancer Institute of Milan publication-title: Ann Surg Oncol – volume: 110 start-page: 62 year: 2019 end-page: 70 article-title: Adjuvant androgen deprivation therapy for poor‐risk, androgen receptor‐positive salivary duct carcinoma publication-title: Eur J Cancer – volume: 10 start-page: 2273 issue: 5 year: 2020 end-page: 2283 article-title: (68)Ga‐PSMA‐HBED‐CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study publication-title: Theranostics – volume: 14 start-page: 1055 year: 2020 article-title: A 10‐year review of primary major salivary gland cancers publication-title: Ecancer Medical Science – volume: 8 start-page: 3946 issue: 3 year: 2017 end-page: 3956 article-title: Management of salivary gland carcinomas: a review publication-title: Oncotarget – volume: 68 start-page: 2146 issue: 9 year: 2010 end-page: 2153 article-title: Fine‐needle aspiration cytology of salivary gland lesions: a systematic review publication-title: J Oral Maxillofac Surg – volume: 45 start-page: 574 issue: 7 year: 2009 end-page: 578 article-title: Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study publication-title: Oral Oncol – volume: 37 start-page: 6083 issue: 15_suppl year: 2019 article-title: NISCAHN: a phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent/metastatic (R/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group publication-title: J Clin Oncol – volume: 11 start-page: 252 issue: 2 year: 2018 end-page: 257 article-title: Second‐line treatment of HER2‐positive salivary gland tumor: ado‐Trastuzumab Emtansine (T‐DM1) after progression on Trastuzumab publication-title: Case Rep Oncol – volume: 16 start-page: 187 year: 2015 end-page: 191 article-title: Mammary analog secretory carcinoma of the parotid gland: a case report and literature review publication-title: Int J Surg Case Rep – volume: 16 start-page: 267 issue: 3 year: 2012 end-page: 283 article-title: Salivary gland carcinomas publication-title: Oral Maxillofac Surg – volume: 36 start-page: 4165 issue: 8 year: 2016 end-page: 4170 article-title: Adjuvant therapy for salivary gland carcinomas publication-title: Anticancer Res – volume: 40 start-page: 323 issue: 3 year: 2017 end-page: 328 article-title: The prognostic significance of facial nerve involvement in carcinomas of the parotid Gland publication-title: Am J Clin Oncol – volume: 135 start-page: 687 issue: 7 year: 2009 end-page: 692 article-title: Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma publication-title: Arch Otolaryngol Head Neck Surg – volume: 7 start-page: 867 issue: 8 year: 1996 end-page: 869 article-title: Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group publication-title: Ann Oncol – volume: 41 start-page: 888 issue: 9 year: 2018 end-page: 893 article-title: Concurrent Chemoradiotherapy in the adjuvant treatment of high‐risk primary salivary Gland malignancies publication-title: Am J Clin Oncol – volume: 9 start-page: 15 issue: 2 year: 2020 article-title: Efficacy of cyclophosphamide, doxorubicin, and cisplatin for adenoid cystic carcinoma, and their relationship with the pre‐chemotherapy tumor growth rate publication-title: Chin Clin Oncol – volume: 10 start-page: 688 issue: 5 year: 2020 end-page: 701 article-title: Targeting HER2 with Trastuzumab Deruxtecan: a dose‐expansion, phase I study in multiple advanced solid tumors publication-title: Cancer Discov – volume: 109 start-page: 1117 issue: 5 year: 2013 end-page: 1122 article-title: Cetuximab and platinum‐based chemoradio‐ or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial publication-title: Br J Cancer – volume: 12 start-page: 815 issue: 8 year: 2011 end-page: 824 article-title: Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review publication-title: Lancet Oncol – volume: 40 start-page: 4240 year: 2022 end-page: 4249 article-title: Phase II study of enzalutamide for patients with androgen receptor‐positive salivary gland cancers (Alliance A091404) publication-title: J Clin Oncol – volume: 4 start-page: 785 issue: 9 year: 1993 end-page: 788 article-title: Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group publication-title: Ann Oncol – volume: 11 start-page: 126 issue: 1 year: 2021 article-title: First experiences with 177Lu‐PSMA‐617 therapy for recurrent or metastatic salivary gland cancer publication-title: EJNMMI Research – volume: 42 start-page: 234 issue: 2 year: 2018 end-page: 246 article-title: Molecular profiling of mammary analog secretory carcinoma revealed a subset of tumors harboring a novel ETV6‐RET translocation: report of 10 cases publication-title: Am J Surg Pathol – volume: 34 start-page: 599 issue: 5 year: 2010 end-page: 608 article-title: Mammary analogue secretory carcinoma of salivary glands, containing the ETV6‐NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity publication-title: Am J Surg Pathol – volume: 137 start-page: 1025 issue: 10 year: 2011 end-page: 1030 article-title: Adjuvant radiation therapy for high‐grade and/or locally advanced major salivary gland tumors publication-title: Arch Otolaryngol Head Neck Surg – volume: 11 year: 2021 article-title: HER2 positivity in histological subtypes of salivary Gland carcinoma: a systematic review and meta‐analysis publication-title: Front Oncol – volume: 36 start-page: 160 issue: 3 year: 2019 end-page: 164 article-title: Milan system for reporting salivary gland cytopathology: An experience with the implication for risk of malignancy publication-title: J Cytol – volume: 119 year: 2021 article-title: A phase II trial of all‐trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma publication-title: Oral Oncol – volume: 279 start-page: 2553 issue: 5 year: 2022 end-page: 2563 article-title: High‐grade salivary gland cancer: is surgery followed by radiotherapy an adequate treatment to reach tumor control? Results from a tertiary referral centre focussing on incidence and management of distant metastases publication-title: Eur Arch Otorhinolaryngol – volume: 8 start-page: 47 year: 2018 article-title: Review of the major and minor salivary glands, part 1: anatomy, infectious, and inflammatory processes publication-title: J Clin Imaging Sci – volume: 39 start-page: 1909 issue: 17 year: 2021 end-page: 1941 article-title: Management of salivary gland malignancy: ASCO guideline publication-title: J Clin Oncol – volume: 51 start-page: 1138 issue: 12 year: 2015 end-page: 1142 article-title: Salivary adenoid cystic carcinoma in Denmark 1990–2005: outcome and independent prognostic factors including the benefit of radiotherapy. Results of the Danish head and neck cancer group (DAHANCA) publication-title: Oral Oncol – volume: 143 start-page: 758 issue: 4 year: 2018 end-page: 766 article-title: A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands publication-title: Int J Cancer – volume: 41 start-page: 1083 year: 2018 end-page: 1088 article-title: Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE‐028 study publication-title: Am J Clin Oncol – volume: 109 start-page: 1 issue: 9 year: 2017 end-page: 10 article-title: Targeting the oncogenic transcriptional regulator MYB in adenoid cystic carcinoma by inhibition of IGF1R/AKT signaling publication-title: J Natl Cancer Inst – volume: 124 start-page: 188 issue: 1 year: 2014 end-page: 195 article-title: Mammary analogue secretory carcinoma: update on a new diagnosis of salivary gland malignancy publication-title: Laryngoscope – volume: 9 year: 2017 – volume: 15 start-page: 803 year: 2015 article-title: Gene expression profiling analysis of CRTC1‐MAML2 fusion oncogene‐induced transcriptional program in human mucoepidermoid carcinoma cells publication-title: BMC Cancer – volume: 27 start-page: 1902 issue: 10 year: 2016 end-page: 1908 article-title: A phase II study of axitinib (AG‐013736) in patients with incurable adenoid cystic carcinoma publication-title: Ann Oncol – volume: 129 start-page: 4276 issue: 10 year: 2019 end-page: 4289 article-title: Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma publication-title: J Clin Invest – ident: e_1_2_9_54_1 doi: 10.1002/hed.25035 – ident: e_1_2_9_22_1 doi: 10.1615/CritRevOncog.2018027598 – ident: e_1_2_9_44_1 doi: 10.1002/cncr.32754 – ident: e_1_2_9_11_1 doi: 10.1102/1470‐7330.2007.0008 – ident: e_1_2_9_115_1 doi: 10.1200/JCO.2022.40.16_suppl.3094 – ident: e_1_2_9_55_1 doi: 10.1002/hed.23940 – ident: e_1_2_9_24_1 doi: 10.1002/lary.26516 – ident: e_1_2_9_63_1 doi: 10.1001/jamaoto.2015.3270 – ident: e_1_2_9_60_1 doi: 10.1016/s1470‐2045(19)30691‐6 – ident: e_1_2_9_86_1 doi: 10.1007/s12105‐021‐01376‐8 – volume-title: WHO Classification of Head and Neck Tumors year: 2017 ident: e_1_2_9_4_1 contributor: fullname: WHO – ident: e_1_2_9_78_1 doi: 10.1200/jco.2007.11.8612 – ident: e_1_2_9_6_1 doi: 10.3332/ecancer.2020.1055 – ident: e_1_2_9_45_1 doi: 10.1002/hed.25891 – ident: e_1_2_9_80_1 doi: 10.1038/bjc.2013.468 – ident: e_1_2_9_33_1 doi: 10.1001/archoto.2009.70 – ident: e_1_2_9_77_1 doi: 10.1016/j.oraloncology.2008.07.010 – ident: e_1_2_9_104_1 doi: 10.1155/2019/5103496 – ident: e_1_2_9_27_1 doi: 10.1016/j.oraloncology.2016.06.019 – ident: e_1_2_9_12_1 doi: 10.1007/s10006‐012‐0350‐9 – ident: e_1_2_9_15_1 doi: 10.21873/anticanres.11659 – ident: e_1_2_9_65_1 doi: 10.1186/1752‐1947‐2‐320 – ident: e_1_2_9_67_1 doi: 10.1002/hed.23925 – ident: e_1_2_9_113_1 doi: 10.1016/s2213‐8587(21)00120‐0 – ident: e_1_2_9_48_1 doi: 10.1177/17588359211013626 – ident: e_1_2_9_82_1 doi: 10.1016/j.oraloncology.2021.105366 – ident: e_1_2_9_101_1 doi: 10.1158/0008‐5472.Can‐10‐1758 – ident: e_1_2_9_10_1 doi: 10.3389/fonc.2020.580141 – ident: e_1_2_9_116_1 doi: 10.1007/s12105‐022‐01420‐1 – ident: e_1_2_9_42_1 doi: 10.1200/jco.2005.05.3025 – ident: e_1_2_9_59_1 doi: 10.1056/NEJMoa1714448 – ident: e_1_2_9_64_1 doi: 10.1172/jci.insight.139497 – ident: e_1_2_9_73_1 doi: 10.1016/s1470‐2045(10)70245‐x – ident: e_1_2_9_69_1 doi: 10.1093/oxfordjournals.annonc.a010770 – ident: e_1_2_9_87_1 doi: 10.7150/thno.38501 – ident: e_1_2_9_89_1 doi: 10.1002/ijc.31353 – ident: e_1_2_9_46_1 doi: 10.1093/annonc/mdw287 – ident: e_1_2_9_88_1 doi: 10.1186/s13550‐021‐00866‐8 – ident: e_1_2_9_93_1 doi: 10.1159/000488669 – ident: e_1_2_9_74_1 doi: 10.21037/cco.2020.03.07 – ident: e_1_2_9_9_1 doi: 10.14694/EdBook_AM.2013.33.257 – ident: e_1_2_9_19_1 doi: 10.1016/j.oraloncology.2017.09.008 – ident: e_1_2_9_68_1 doi: 10.1001/archotol.1981.00790480015004 – ident: e_1_2_9_51_1 doi: 10.1200/jco.18.00545 – ident: e_1_2_9_29_1 doi: 10.1001/archoto.2011.158 – ident: e_1_2_9_118_1 doi: 10.1158/1078‐0432.Ccr‐13‐2098 – volume: 36 start-page: 4165 issue: 8 year: 2016 ident: e_1_2_9_34_1 article-title: Adjuvant therapy for salivary gland carcinomas publication-title: Anticancer Res contributor: fullname: Sayan M – ident: e_1_2_9_13_1 doi: 10.1200/JCO.21.00449 – ident: e_1_2_9_28_1 doi: 10.1186/s13014‐018‐1130‐y – ident: e_1_2_9_38_1 doi: 10.1200/jop.2017.026856 – ident: e_1_2_9_94_1 doi: 10.3389/fonc.2021.693394 – ident: e_1_2_9_37_1 doi: 10.1007/s00405‐021‐07024‐9 – ident: e_1_2_9_90_1 doi: 10.1001/jamaoto.2015.3930 – ident: e_1_2_9_105_1 doi: 10.1016/j.oooo.2020.04.007 – ident: e_1_2_9_31_1 doi: 10.1016/j.adro.2017.03.008 – ident: e_1_2_9_83_1 doi: 10.1093/jnci/djx017 – ident: e_1_2_9_18_1 doi: 10.1097/coc.0000000000000157 – ident: e_1_2_9_52_1 doi: 10.1016/j.annonc.2019.11.018 – ident: e_1_2_9_5_1 doi: 10.1111/apm.12901 – ident: e_1_2_9_50_1 doi: 10.1634/theoncologist.2012‐0369 – ident: e_1_2_9_76_1 doi: 10.1002/hed.23647 – ident: e_1_2_9_102_1 doi: 10.1016/j.ijscr.2015.09.031 – ident: e_1_2_9_85_1 doi: 10.1016/j.nucmedbio.2021.04.003 – ident: e_1_2_9_99_1 doi: 10.3342/ceo.2011.4.4.188 – ident: e_1_2_9_3_1 doi: 10.4103/jcis.JCIS_46_18 – ident: e_1_2_9_61_1 doi: 10.1186/s12885‐015‐1827‐3 – ident: e_1_2_9_43_1 doi: 10.1200/jco.18.01859 – ident: e_1_2_9_58_1 doi: 10.1200/jco.21.00468 – ident: e_1_2_9_110_1 doi: 10.1056/NEJMoa2005651 – ident: e_1_2_9_36_1 doi: 10.1016/j.critrevonc.2014.02.002 – ident: e_1_2_9_106_1 doi: 10.1097/PAS.0b013e3181d9efcc – ident: e_1_2_9_66_1 doi: 10.18632/oncotarget.13952 – ident: e_1_2_9_114_1 doi: 10.1200/JCO.2021.39.15_suppl.3079 – ident: e_1_2_9_112_1 doi: 10.1016/s1470‐2045(21)00247‐3 – ident: e_1_2_9_53_1 doi: 10.1200/JCO.2019.37.15_suppl.6001 – ident: e_1_2_9_47_1 doi: 10.1200/JCO.2022.40.16_suppl.6020 – ident: e_1_2_9_96_1 doi: 10.1097/cco.0000000000000527 – ident: e_1_2_9_21_1 doi: 10.1016/j.joms.2009.09.064 – ident: e_1_2_9_26_1 doi: 10.1016/j.ijrobp.2004.03.018 – ident: e_1_2_9_72_1 doi: 10.1002/1097‐0142(19911101)68:9<1874::aid‐cncr2820680904>3.0.co;2‐s – ident: e_1_2_9_97_1 doi: 10.1016/j.ejca.2018.12.035 – ident: e_1_2_9_49_1 doi: 10.1200/JCO.2022.40.16_suppl.6046 – ident: e_1_2_9_103_1 doi: 10.1002/lary.24254 – ident: e_1_2_9_23_1 doi: 10.1002/cncr.21083 – ident: e_1_2_9_25_1 doi: 10.1016/j.oraloncology.2015.10.002 – ident: e_1_2_9_32_1 doi: 10.1186/s12885‐018‐4578‐0 – ident: e_1_2_9_117_1 doi: 10.1016/j.ejca.2011.06.012 – ident: e_1_2_9_79_1 doi: 10.1172/jci128227 – ident: e_1_2_9_7_1 doi: 10.1097/coc.0000000000000429 – ident: e_1_2_9_71_1 doi: 10.1002/1097‐0142(20010201)91:3<541::aid‐cncr1032>3.0.co;2‐y – ident: e_1_2_9_84_1 doi: 10.1038/s41392‐022‐00934‐y – ident: e_1_2_9_100_1 doi: 10.1038/s41467‐018‐08069‐x – ident: e_1_2_9_111_1 doi: 10.1056/NEJMoa2005653 – ident: e_1_2_9_92_1 doi: 10.1016/j.ctrv.2020.102069 – ident: e_1_2_9_62_1 doi: 10.1002/gcc.20306 – ident: e_1_2_9_8_1 doi: 10.1200/JCO.2019.37.15_suppl.6083 – ident: e_1_2_9_56_1 doi: 10.1093/annonc/mdx771 – ident: e_1_2_9_95_1 doi: 10.1158/2159‐8290.Cd‐19‐1014 – ident: e_1_2_9_57_1 doi: 10.1200/jco.22.00229 – ident: e_1_2_9_75_1 doi: 10.1002/hed.24933 – ident: e_1_2_9_14_1 doi: 10.1016/j.critrevonc.2020.102959 – ident: e_1_2_9_17_1 doi: 10.1002/lio2.326 – ident: e_1_2_9_70_1 doi: 10.1093/oxfordjournals.annonc.a058665 – ident: e_1_2_9_108_1 doi: 10.1097/pas.0000000000001065 – ident: e_1_2_9_91_1 doi: 10.1002/hed.23350 – ident: e_1_2_9_2_1 doi: 10.4103/jcis.JCIS_45_18 – ident: e_1_2_9_35_1 doi: 10.1097/coc.0000000000000386 – ident: e_1_2_9_16_1 doi: 10.1097/md.0000000000005964 – ident: e_1_2_9_109_1 doi: 10.1097/pas.0000000000000972 – ident: e_1_2_9_20_1 doi: 10.4103/joc.Joc_165_18 – ident: e_1_2_9_107_1 doi: 10.1016/s1470‐2045(19)30856‐3 – ident: e_1_2_9_81_1 doi: 10.1084/jem.20180939 – ident: e_1_2_9_98_1 doi: 10.1007/s00405‐015‐3855‐7 – ident: e_1_2_9_40_1 doi: 10.1001/archotol.130.7.849 – ident: e_1_2_9_39_1 doi: 10.1093/jjco/hyn045 – ident: e_1_2_9_30_1 doi: 10.1016/j.oraloncology.2015.02.096 – ident: e_1_2_9_41_1 doi: 10.1007/bf02574486 |
| SSID | ssj0003642 |
| Score | 2.488952 |
| SecondaryResourceType | review_article |
| Snippet | Salivary gland carcinomas (SGC) are a rare and variable group of head and neck cancers with historically poor response to cytotoxic chemotherapy and... |
| SourceID | proquest crossref pubmed wiley |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 1315 |
| SubjectTerms | adenoid cystic carcinoma Androgen receptors Carcinoma Chemotherapy Clinical trials Cytotoxicity ErbB-2 protein Gene Fusion Head & neck cancer Head and Neck Neoplasms Humans Immunotherapy Metastases mucoepidermoid carcinoma Notch protein Oral cancer precision therapy Receptor mechanisms salivary duct carcinoma Salivary gland salivary gland cancer Salivary Gland Neoplasms - pathology Salivary Glands - pathology |
| Title | A molecular guide to systemic therapy in salivary gland carcinoma |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhed.27307 https://www.ncbi.nlm.nih.gov/pubmed/36859797 https://www.proquest.com/docview/2795927997 https://search.proquest.com/docview/2781624368 |
| Volume | 45 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEA7akxcf-KpWieLBy9p288ZTsS09iaCCtyWv1R66K9320H9vHt2VIoLgZVmYhCyTzORLZucbAG4wwxQzrROqiU4wMSbhVshEWucMU00sCWz7k2f2-MaHI0-Tc1_nwkR-iObCzVtG8NfewKWqut-koR_W3Lm9N2SSu1NCSN9AT40XRhTHSCdG_n4F16xCvbTb9Nzci34AzE28Gjac8d6_PnUf7K5xJhzEhXEAtmxxCAYDOKvL4cL35dRYuChhJHOeahhzsVZwWsBK-hDRfAVDiQ-ofcWhopzJI_A6Hr08TJJ1DYVEI4JYklM3R7THTN9YowURnCPZl7ynFBFGG6EcPmAsR1J5KZZYYUuozlFOscxTdAxaRVnYUwCRx1LMuAOKOxIyQjlXHk05BKdlKphqg-tam9lnpMrIIilymjkNZEEDbdCp9ZytraVyEje0ewgnvmrEbp374IUsbLn0bXifpp4vvw1O4vw0o3gSfcF879swDb8Pn01Gw_By9vem52DH15iPfzl2QGsxX9oLsF2Z5WVYcl_7vdWi |
| link.rule.ids | 315,782,786,1408,27933,27934,46064,46488 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEA5aD3rxga_6jOLBy9p281zwUrRSsRbBCt6WbJLVHroVaw_992aS7oqIIHhZFiZhlslM8iXZ-QahMyoop0LriGumI8qMiaRNVKSsmwxjzSzzbPvdR9F_ltcdoMm5LHNhAj9EdeAGkeHnawhwOJBufLGGvlpz4RZfSCVfcgqlT-AgD9U8TDgNd52UwAkLLXmFmnGj6vp9NfoBMb8jVr_k3Kz972PX0eocauJ28I0NtGCLTdRu41FZERe_TIfG4o8xDnzOQ41DOtYMDws8UXBL9D7DvsoH1lB0qBiP1BZ6uukMrrrRvIxCpAkjIsq5GybeFKZlrNEJS6QkqqVkM8tYYrRJMgcRhMiJykBKFc2oZVznJOdU5THZRrViXNhdhAnAKWHcHsXtCgXjUmYAqByI0ypORFZHp6U507fAlpEGXuQ4dRZIvQXq6KA0dDoPmImTONXukTjxSSV2rg73F6qw4ym0kS0eA2V-He2EAaq0AI9-IqD3uR-H39Wn3c61f9n7e9NjtNwd3PfS3m3_bh-tQMn58NPjAap9vE_tIVqcmOmR979Pj-bZyg |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NS8MwFA86Qbz4gV_TqVE8eKluzVeLp-E2JsoYqOCtpEmqO6wd23rYf29es1aGCIKXUngJKe8lL7_k9f0eQtdUUE6FUh5XTHmUae0FJpSeNNYZ-ooZVrDt91_E4D3odIEm577MhXH8ENWFG6yMwl_DAp_o5O6bNPTT6Fu790Im-Qa1MByI8wkZVm6YcOpCnZTABQstaYWa_l3VdXUz-oEwVwFrseP0dv71rbtoewk0cdvNjD20ZtJ91G7jcVkPF3_kI23wPMOOzXmksEvGWuBRimcSYkTTBS5qfGAFJYfSbCwP0Fuv-_rQ95ZFFDxFGBFewq2ReFPoljZahSwMAiJbMmjGMQu10mFsAYIQCZExSKmkMTWMq4QknMrEJ4eolmapOUaYAJgS2p5Q7JlQMB4EMcApC-GU9EMR19FVqc1o4rgyIseK7EdWA1GhgTpqlHqOlstlZiV2aPsIrfiyEtuJDtELmZoshzZBi_tAmF9HR84-1SjAoh8K6H1TmOH34aN-t1O8nPy96QXaHHZ60fPj4OkUbUG9effHYwPV5tPcnKH1mc7Pi9n3BQUN2HA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+molecular+guide+to+systemic+therapy+in+salivary+gland+carcinoma&rft.jtitle=Head+%26+neck&rft.au=Weaver%2C+Alice+N.&rft.au=Lakritz%2C+Stephanie&rft.au=Mandair%2C+Divneet&rft.au=Ulanja%2C+Mark+B.&rft.date=2023-05-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.issn=1043-3074&rft.eissn=1097-0347&rft.volume=45&rft.issue=5&rft.spage=1315&rft.epage=1326&rft_id=info:doi/10.1002%2Fhed.27307&rft.externalDBID=10.1002%252Fhed.27307&rft.externalDocID=HED27307 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1043-3074&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1043-3074&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1043-3074&client=summon |